Griffithsin-based Rectal Microbicide for PREvention of Viral ENTry (PREVENT)
NCT04032717 is a phase 1 interventional trial sponsored by Rhonda Brand. As of 21 Nov 2026, it was terminated. It studies Q-Griffithsin enema in HIV Prevention. The registry lists an enrollment of 18 participants at 1 site in 1 country. The registry lists a start date of 10 Jul 2019 and a primary completion date of 4 Feb 2021.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT04032717 |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Rhonda Brand |
| Enrollment | 18 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | HIV Prevention |
| Drugs | Q-Griffithsin enema |
| Start | 10 Jul 2019 |
| Primary completion | 4 Feb 2021 |
| Study completion | 4 Feb 2021 |
| Last update posted | 6 Jul 2023 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Ken Ho, MD
University of Pittsburgh
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hiv/aids Clinical Research Unit / University of Pittsburgh
Pittsburgh
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT04032717
Each answer restates registry values shown on this page.
What is NCT04032717?
NCT04032717 is a phase 1 interventional trial sponsored by Rhonda Brand. It studies Q-Griffithsin enema in HIV Prevention.
Who leads NCT04032717?
The registry names Ken Ho, MD (principal investigator, University of Pittsburgh) as the overall official.
Where does NCT04032717 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT04032717 study?
The registered drug and biological interventions are Q-Griffithsin enema.
When did NCT04032717 end?
The registry lists a primary completion date of 4 Feb 2021 and a study completion date of 4 Feb 2021. The sponsor last updated the record on 6 Jul 2023.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.